16.05.2024 • News

MOL Inaugurates €1.3 Billion Polyols Complex in Hungary

Hungarian energy and petrochemicals group MOL has inaugurated its €1.3 billion polyol complex in Tiszaújváros, Hungary, with a capacity of around 200,000 t/y of polyol, a widely used plastic raw material.

According to MOL, the commissioning is a significant milestone, as it is the only company in Hungary and Central and Eastern Europe that covers the entire value chain from crude oil processing to polyol production.

The new polyol complex is MOL’s largest organic investment and the respective license agreement was signed by MOL, Thyssenkrupp and Evonik IP in summer 2017. The groundbreaking took place in September 2019.

In addition to the four main plants, a pilot polyol plant, a quality assurance laboratory and, in Százhalombatta, a research and development center were also built.

" This investment has put Tiszaújváros back on the map of the European chemical industry, making it one of the most important industrial centers in the region. It will enhance the industrial competitiveness of our country and could catalyze economic growth as well," said Zsolt Hernádi, chairman and CEO of MOL Group.

“With this new MOL polyol-complex we establish new standards in terms of efficiency, environmental friendliness and automation by combining proven technologies with innovative solutions”, said Nadja Håkansson, CEO of Thyssenkrupp Uhde.

Polyol is one of the most sought-after plastics raw materials, used in a wide range of industries from car manufacturing to clothing and insulation. Polyurethane is made from polyol and is the base material for many of the durable consumer goods.

© MOL Group
© MOL Group

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read